WOBURN, Mass.--(BUSINESS WIRE)--
ArQule, Inc. (ARQL) today announced that it will report its financial results for the fiscal 2013 year-end and fourth quarter on Wednesday, March 5, 2014 at 7:00 a.m. eastern time. The Company will hold a conference call at 9:00 a.m. eastern time that day to discuss these results.
Conference Call and Webcast
|Date:||Wednesday, March 5, 2014|
|Time:||9:00 a.m., Eastern Time|
Conference Call Numbers
|Domestic (toll free):||(877) 868-1831|
A replay of the conference call will be available beginning on March 5, 2014 two hours after the call’s completion for seven days and can be accessed by dialing toll-free (855) 859-2056 or (800) 585-8367 and outside the U.S. (404) 537-3406. The confirmation code for replayed calls is 31423627.
ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule’s lead product, in Phase 2 and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor tyrosine kinase. The Company’s pipeline includes: ARQ 092, designed to inhibit the AKT serine/threonine kinase, and ARQ 087, designed to inhibit fibroblast growth factor receptor (FGFR). ArQule’s current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase.
- Health Care Industry
- Company Earnings
William B. Boni, 781-994-0300
VP, Investor Relations/